Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 16243151.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 44 patients treated with arsenic trioxide (As2(O3)) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2(O3).
Medical subject headings
- Antineoplastic Agents
- Arsenicals
- Herpes Zoster
- Oxides